Rheumatoid Arthritis

Uncertainty on Pre-Clinical RA – Rheumatologist Survey Results

Save

Jack Cush, MD

Sep 27, 2023

In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.

In the last few years there have been numerous well designed and appropriately powered randomized clinical trials of pre

Read Article

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring #RA https://t.co/w1GKoDvvKS https://t.co/hyBFcEvImI

RheumNow @Dr. John Cush( View Tweet )

Sep 25, 2023

Advice on Multi-Drug Failures in RA

Save

Jack Cush, MD

Sep 25, 2023

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.

As many of us struggle with multi-drug

Read Article

Systematic review of #RA RCTs shows that the number needed to treat (NNT) for 2nd-generation biologics success is 4-6 to achieve one ACR50 response, while withdrawals due to adverse events were few and non-significant https://t.co/sbU40aTvHN https://t.co/9Ce3LbRwmg

RheumNow @Dr. John Cush( View Tweet )

Sep 25, 2023

Assessing Cardiovascular Risks: The Responsibility of the Rheumatologist In 2016, EULAR posted recommendations for the management of cardiovascular (CV) risks in patients with rheumatoid arthritis (#RA) and other inflammatory joint diseases (IJ D)1. https://t.co/OhE44GkvMB https://t.co/XhoTah7PTp

RheumNow @Dr. John Cush( View Tweet )

Sep 24, 2023

#RA QD Clinic: Induced inflammatory arthritis Dr. David Liew, a rheumatologist in Melbourne, Australia, discusses induced inflammatory arthritis as part of RheumNow's Hard Decisions in RA campaign https://t.co/Wble2GZqD4 @drdavidliew https://t.co/kcwCw4JPB8

RheumNow @Dr. John Cush( View Tweet )

Sep 24, 2023

#RA QD Clinic: Cardiovascular Risk and RA Features Dr. Kathryn Dao (Dallas, TX) A high Risk RA patients - how to manage the cardiovascular risks. https://t.co/jc3fvaP9l3 https://t.co/tYswHxqnNX

RheumNow @Dr. John Cush( View Tweet )

Sep 22, 2023

TNR: Decisions in Methotrexate This Tuesday Night Rheumatology panel discussion on "MTX Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer. The Panel discussed folate & MTX dosing, side effect management, and more. https://t.co/Q44VYhgAzJ https://t.co/4ndTBvS1mc

RheumNow @Dr. John Cush( View Tweet )

Sep 22, 2023

Join us for our final webinar this month, DMARD Choices & Changes. The panel will discuss rheumatologists' choices in choosing 2nd line & 3rd line DMARD therapy, when or if to wean/de-escalate DMARDs and how to proceed with restarting therapy when needed. https://t.co/cRb1E79QLB https://t.co/JbRp3P1TO8

RheumNow @Dr. John Cush( View Tweet )

Sep 22, 2023

Pilot trial shows montelukast added to csDMARDs in ative RA pts may improve clinical outcomes. 92, enrolled, 87 completed 16 wk trial; given either PBO or MONT. MONT pts had signif improvement in DAS28, QoL & sVCAM levels (p<0.01). https://t.co/NnOIXGzmOV https://t.co/Rf0OeT28iW

RheumNow @Dr. John Cush( View Tweet )

Sep 21, 2023

The EMA has approved an anti-IL-6/tocilizumab biosimilar, manufactured by Fresenius-Kabi, and called Tyenne. This is the 1st TCZ biosimilar, indicated for use in RA, Systemic JIA, poly-JIA, GCA, COVID-19 and CAR-T cell-induced cytokine release syndrome https://t.co/KGhOqmmjWe https://t.co/VGwNRSI0ls

RheumNow @Dr. John Cush( View Tweet )

Sep 21, 2023

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring

Save

Blair Solow, MD, MSc

Sep 21, 2023

We use biologic agents on a daily basis in the treatment of rheumatoid arthritis. Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment.

Read Article

#RA QD Clinic: Enough with the Steroids Features Dr. Jack Cush RA patient not doing well - Should you use Steroids? How much, how long & guideline guidance RA QD Clinics are video vignettes with lessons from the clinic. https://t.co/dOpTwhkuIP https://t.co/dJmjHyKSS3

RheumNow @Dr. John Cush( View Tweet )

Sep 21, 2023

#RA Associated Cancer Risk A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis. https://t.co/DcOKi1DXsh https://t.co/8cRLYkXcRL

RheumNow @Dr. John Cush( View Tweet )

Sep 21, 2023

TNR: Decisions in Methotrexate

Save

Jack Cush, MD

Sep 20, 2023

This Tuesday Night Rheumatology panel discussion on "Methotrexate Decisions" features Drs. Michael Weinblatt, Grace Wright, Richard Conway and Joel Kremer. The Panel discussed folate & MTX dosing, side effect management, MTX & lung disease and optimal monitoring, with many audience

Read Article

RA Associated Cancer Risk

Save

Jack Cush, MD

Sep 19, 2023

A large cohort analysis of insured rheumatoid arthritis (RA) patients reveals that RA patients have a 1.69 to 2.08 fold higher risk of developing cancer, especially lymphoma or lung cancer, within 1 year of RA diagnosis.

The analysis included nationwide health insurance claims data

Read Article

Which #RA patients do you screen for ILD?

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

Tomorrow! Join us for Decisions in MTX at 7pm ET. https://t.co/SRjj64QPeW https://t.co/JSAPjDxKYn

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

#RA and MSK Ultrasound Dr. Eric Dein, a rheumatologist in Summit, NJ, discusses musculoskeletal ultrasound in rheumatoid arthritis as part of RheumNow's Hard Decisions in RA campaign. https://t.co/vMZVdL1jVM @ericdeinmd https://t.co/feAr77hVax

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

QD Clinic: RA and medication induced ulcers Dr. Bella Mehta, a rheumatologist from New York, presents this QD clinic on medication induced ulcers as part of RheumNow's Hard Decisions in #RA campaign. https://t.co/AVjUYltVvK https://t.co/mVI1oQob0Z

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

Adalimumab Biosimilars: Realizing the Promise of Market Competition Over four years after adalimumab biosimilars were first launched in the European Union and elsewhere, adalimumab biosimilars have finally become available in the United States. https://t.co/5TqqTtkSLS https://t.co/oLNbweXtPb

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

Japanese study of 106 RA pts starting ABA, TCZ or TNFi. Among the 37 starting ABA, 17 were + for HLA-DRB1*04:05 who were uniquely responsive (SDAI50=71%) compared to those without *04:05 haplotype (30%) (p=0.022) https://t.co/3tQz84vK1T https://t.co/XL7aRKCmDx

RheumNow @Dr. John Cush( View Tweet )

Sep 18, 2023

Yoga's Biologic benefits? 64 active #RA pts (DAS28~4.6) Rx w/ yoga (or not) x 8 wks. A modest, significant reduced DAS28 in Yoga grp (4.7 to 3.8) but not control (4.5 -4.3), Yoga had signif reductions in RORγt, IL-17, IL-6, CXCL2, CXCR2, & incr in TREGs https://t.co/hSrZ3cOFtU https://t.co/CXfHZV95XA

RheumNow @Dr. John Cush( View Tweet )

Sep 17, 2023

Hydroxychloroquine Adherence Lowers Cardiovascular Risks A new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients. https://t.co/XzXcBP7XoO https://t.co/V2EQJ2GlpC

RheumNow @Dr. John Cush( View Tweet )

Sep 16, 2023

Watch Drs. Janet Pope and Alvin Wells debate Triple DMARD Therapy Drs. Janet Pope and Alvin Wells debate triple DMARD therapy. These and more debates and perspectives on Hard Decisions in #RA now available. https://t.co/f59Wh3lnHX @janetbirdope @alvinwellsmd https://t.co/H2F4wOElSw

RheumNow @Dr. John Cush( View Tweet )

Sep 16, 2023